Curi RMB Capital LLC raised its position in West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) by 3.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 72,650 shares of the medical instruments supplier's stock after buying an additional 2,614 shares during the period. Curi RMB Capital LLC owned about 0.10% of West Pharmaceutical Services worth $21,807,000 at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. Kayne Anderson Rudnick Investment Management LLC boosted its stake in shares of West Pharmaceutical Services by 6.8% in the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 593,692 shares of the medical instruments supplier's stock worth $195,556,000 after acquiring an additional 37,702 shares during the last quarter. Sei Investments Co. boosted its stake in West Pharmaceutical Services by 12.7% during the 2nd quarter. Sei Investments Co. now owns 401,026 shares of the medical instruments supplier's stock worth $132,095,000 after purchasing an additional 45,208 shares during the last quarter. Envestnet Asset Management Inc. grew its holdings in shares of West Pharmaceutical Services by 9.8% during the second quarter. Envestnet Asset Management Inc. now owns 301,339 shares of the medical instruments supplier's stock worth $99,258,000 after buying an additional 26,947 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of West Pharmaceutical Services by 11.7% during the second quarter. Dimensional Fund Advisors LP now owns 288,639 shares of the medical instruments supplier's stock worth $95,075,000 after buying an additional 30,253 shares in the last quarter. Finally, Epoch Investment Partners Inc. raised its position in shares of West Pharmaceutical Services by 3.5% in the second quarter. Epoch Investment Partners Inc. now owns 269,675 shares of the medical instruments supplier's stock valued at $88,828,000 after buying an additional 9,156 shares during the last quarter. 93.90% of the stock is currently owned by hedge funds and other institutional investors.
West Pharmaceutical Services Price Performance
WST traded down $5.88 on Thursday, reaching $338.12. 572,232 shares of the company's stock were exchanged, compared to its average volume of 571,904. West Pharmaceutical Services, Inc. has a twelve month low of $265.00 and a twelve month high of $413.70. The stock has a market cap of $24.49 billion, a PE ratio of 51.06, a P/E/G ratio of 24.78 and a beta of 1.00. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.00 and a quick ratio of 2.23. The stock's fifty day moving average price is $304.87 and its 200-day moving average price is $316.60.
West Pharmaceutical Services (NYSE:WST - Get Free Report) last released its earnings results on Thursday, October 24th. The medical instruments supplier reported $1.85 earnings per share for the quarter, topping analysts' consensus estimates of $1.50 by $0.35. The business had revenue of $746.90 million for the quarter, compared to analyst estimates of $709.62 million. West Pharmaceutical Services had a net margin of 17.37% and a return on equity of 18.41%. The business's revenue was down .1% on a year-over-year basis. During the same period last year, the company posted $2.16 EPS. Sell-side analysts expect that West Pharmaceutical Services, Inc. will post 6.66 EPS for the current year.
West Pharmaceutical Services Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 20th. Shareholders of record on Wednesday, November 13th will be paid a $0.21 dividend. The ex-dividend date is Wednesday, November 13th. This is an increase from West Pharmaceutical Services's previous quarterly dividend of $0.20. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.25%. West Pharmaceutical Services's dividend payout ratio (DPR) is 11.87%.
Insider Transactions at West Pharmaceutical Services
In other news, VP Charles Witherspoon sold 703 shares of the firm's stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $310.40, for a total transaction of $218,211.20. Following the completion of the sale, the vice president now owns 1,253 shares in the company, valued at $388,931.20. This trade represents a 35.94 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.53% of the company's stock.
West Pharmaceutical Services Company Profile
(
Free Report)
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Featured Articles
Before you consider West Pharmaceutical Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.
While West Pharmaceutical Services currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
